---
figid: PMC5951071__ceo-2017-01606f2
figtitle: Pathogenetic mechanism of Samter’s triad
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Danio rerio
- Homo sapiens
pmcid: PMC5951071
filename: ceo-2017-01606f2.jpg
figlink: /pmc/articles/PMC5951071/figure/f2-ceo-2017-01606/
number: F2
caption: 'Pathogenetic mechanism of Samter’s triad. Aspirin inhibits the cyclooxygenase
  (COX) pathway and diverts arachidonic acid metabolites to the lipoxygenase (LO)
  pathway. By inhibition of COX-1, the production of prostaglandin E2 (PGE2) decreases.
  Low levels of PGE2 lead to increased synthesis of cysteinyl leukotrienes (Cys-LTs).
  The inhibition of COX-2 might lead to a structural change in the enzyme, which results
  in the increase of prostaglandin D2 (PGD2). PLA2, phospholipase A2; FLAP, 5-LO activating
  protein; HPETE, hydroperoxyeicosatetraenoic acid; PGG2, prostaglandin G2; LTA4,
  leukotriene A4; PGH2, prostaglandin H2; LTC4, leukotriene C4; ASA: acetylsalicylic
  acid, NSAID, nonsteroidal anti-inflammatory drug; LTB4, leukotriene B4; LTD4, leukotriene
  D4; LTE4, leukotriene E4.'
papertitle: 'Samter’s Triad: State of the Art.'
reftext: Sung-Dong Kim, et al. Clin Exp Otorhinolaryngol. 2018 Jun;11(2):71-80.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.816266
figid_alias: PMC5951071__F2
figtype: Figure
redirect_from: /figures/PMC5951071__F2
ndex: 52cf2a7f-df1f-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5951071__ceo-2017-01606f2.html
  '@type': Dataset
  description: 'Pathogenetic mechanism of Samter’s triad. Aspirin inhibits the cyclooxygenase
    (COX) pathway and diverts arachidonic acid metabolites to the lipoxygenase (LO)
    pathway. By inhibition of COX-1, the production of prostaglandin E2 (PGE2) decreases.
    Low levels of PGE2 lead to increased synthesis of cysteinyl leukotrienes (Cys-LTs).
    The inhibition of COX-2 might lead to a structural change in the enzyme, which
    results in the increase of prostaglandin D2 (PGD2). PLA2, phospholipase A2; FLAP,
    5-LO activating protein; HPETE, hydroperoxyeicosatetraenoic acid; PGG2, prostaglandin
    G2; LTA4, leukotriene A4; PGH2, prostaglandin H2; LTC4, leukotriene C4; ASA: acetylsalicylic
    acid, NSAID, nonsteroidal anti-inflammatory drug; LTB4, leukotriene B4; LTD4,
    leukotriene D4; LTE4, leukotriene E4.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - CG42237
  - COX4
  - COX5A
  - flap
  - AstA
  - COX1
  - COX2
  - ptgs1
  - lta
  - PLA2G1B
  - PLA2G2A
  - PLA2G6
  - PLA2G3
  - PLA2G5
  - PLA2G7
  - PLA2G10
  - PLA2G12A
  - PLA2G12B
  - PLA2G2C
  - PLA2G2D
  - PLA2G2E
  - PLA2G2F
  - PLA2G4A
  - PLA2G4C
  - PLA2G4D
  - COX8A
  - CPOX
  - COX5B
  - COX6C
  - COX7C
  - .na.character
  - COX4I1
  - COX4I2
  - COX6A1
  - COX6A2
  - COX6B1
  - COX6B2
  - COX7A1
  - COX7A2
  - COX7B
  - COX7B2
  - COX8C
  - ALOX5AP
  - ALOX5
  - ARSA
  - PTGS1
  - LTA
  - PTGS2
  - PTGDS
  - HPGDS
  - Arachidonic acid
  - 5-HPETE
  - PGG2
  - Cys
  - PGE2
---
